Scientific Summary: New York Valves 2025: The Structural Heart Summit – Late-Breaking Clinical Trials (June 25–27, 2025) Latest Update coverage: July 22, 2025 | Medical News Media
Scientific Summary:
New York Valves 2025:
The Structural Heart Summit – Late-Breaking Clinical Trials (June 25–27, 2025)
Latest Update coverage: July 22, 2025 | Medical News Media
Overview:
• New York Valves 2025 (June 25–27, NYC) was organized by the Cardiovascular Research Foundation (CRF), replacing the former TCT-Valves conference.It is a new international heart meeting focused on valve diseases and minimally invasive treatments.
• The agenda included live cases, clinical science sessions, and 150+ abstracts. Each day focused on a specific heart valve:
• Day 1: Aortic valve
• Day 2: Tricuspid valve
• Day 3: Mitral valve
Day 1 – Aortic Valve Trials (June 25):
1. EARLY TAVR Trial: Early treatment of severe aortic valve narrowing may be better than waiting.
2. DETECT AS Trial: Using digital alerts helped reduce treatment delays for women.
3. Redo TAVR Study: Analyzed outcomes of doing TAVR again or removing old valves.
4. New Valve Design: Early results from a self-expanding valve used in the U.S. were promising.
Day 2 – Tricuspid Valve Trials (June 26):
1. TRILUMINATE Study: Showed how tricuspid disease worsens without treatment.
2. TRISCEND II: One-year follow-up showed improved heart valve function after valve replacement.
3. Tri-QOL Study: Defined what counts as a good result after tricuspid procedures.
4. TRISPA Registries: Found that other valve problems affect outcomes after tricuspid repair.
Day 3 – Mitral Valve Trials (June 27):
1. Intrepid TMVR: Two-year results showed success with a new mitral valve placed through a leg vein.
2. PASCAL System Study: Patients had better quality of life after using the PASCAL mitral system.
3. Global Disease Report: Showed how common mitral valve disease is worldwide.
4. Polymeric Valve Study: A new plastic-based mitral valve worked well after 1 year.
Extra Highlight:
• A special Left Atrial Appendage Closure (LAAC) session was held on June 26.
This update showing how valve disease treatment is evolving quickly, with a focus on minimally invasive solutions and better outcomes for patients.
https://pubmed.ncbi.nlm.nih.
